Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDVN > SEC Filings for MDVN > Form 8-K on 22-Apr-2013All Recent SEC Filings

Show all filings for MEDIVATION, INC. | Request a Trial to NEW EDGAR Online Pro



Other Events

Item 8.01 Other Events.

On April 15, 2013, Medivation, Inc. (the "Company") filed a Notice of Appeal in its ongoing litigation against Aragon Pharmaceuticals, Inc. ("Aragon"). The appeal seeks reversal of summary adjudication rulings made in December 2012 and January 2013 by the Superior Court of the City and County of San Francisco, ruling that Aragon has exclusive rights to a small molecule known as "ARN509" that is in development for castration-resistant prostate cancer. The Company believes it is the exclusive licensee of ARN509, based on agreements between the Company and The Regents of the University of California (the "Regents"), and in 2011 filed a lawsuit seeking to enforce its rights.

The Company's appeal of the summary adjudication rulings in Aragon's favor will be heard by the First Appellate District of the California Court of Appeals. Under California law, the appeals court will review the summary adjudication rulings "de novo," without deference to the findings of the trial court judge. Information contained on websites of various legal professionals who practice before the California Courts of Appeal state that the appeals process generally takes 12 to 18 months.

In its 2011 lawsuit, the Company also brought related claims against the Regents and Dr. Michael Jung, a professor at UCLA, alleging, among other things, breach of contract against the Regents and fraud against Dr. Jung.

The trial court's December 2012 and January 2013 summary adjudication rulings also found in favor of Regents on the Company's claims against the Regents. Under California law, the Company cannot appeal this decision until after resolution of counterclaims brought by the Regents alleging that the Company is obligated to pay the Regents 10% of any sales milestone payments the Company may receive under its 2009 collaboration agreement with Astellas Pharma Inc. covering the global development and commercialization of enzalutamide. Trial on the Regents' counterclaims is scheduled to occur in July 2013. Thereafter, when a final judgment is entered on claims between the Company and Regents, the Company intends to appeal the summary adjudication rulings in favor of the Regents.

The Company's fraud claims against Dr. Jung are scheduled to go to trial in October 2013.

  Add MDVN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDVN - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.